Trastuzumab Deruxtecan + Chemotherapy
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Endometrial Cancer
Conditions
Endometrial Cancer
Trial Timeline
Sep 30, 2025 → Mar 23, 2032
NCT ID
NCT07022483About Trastuzumab Deruxtecan + Chemotherapy
Trastuzumab Deruxtecan + Chemotherapy is a phase 3 stage product being developed by Daiichi Sankyo for Endometrial Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07022483. Target conditions include Endometrial Cancer.
What happened to similar drugs?
0 of 20 similar drugs in Endometrial Cancer were approved
Approved (0) Terminated (0) Active (20)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07022483 | Phase 3 | Recruiting |
Competing Products
20 competing products in Endometrial Cancer